Progress of ctDNA in predicting prognosis of patients with urological tumors

Progress of ctDNA in predicting prognosis of patients with urological tumors

2024.01.18
Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was held from April 14 to 19, 2023, in Orlando, USA. In this AACR conference, three ctDNA-related studies evaluated its application value in urological tumors.
ESMO 2023 | Dr. Henrik Grönberg: Outcome Adaptive Design and Biomarker-Based Treatment Selection

ESMO 2023 | Dr. Henrik Grönberg: Outcome Adaptive Design and Biomarker-Based Treatment Selection

2023.11.06
Prostate cancer remains a significant global health concern, predominantly affecting men. In recent groundbreaking research led by Dr. Henrik Grönberg, a novel approach known as outcome adaptive design was implemented to revolutionize the assessment of different drugs simultaneously. This innovative study design incorporated the dynamic adjustment of randomization probabilities based on individual patient outcomes, enabling the selection of the most suitable treatment for each person. Furthermore, the study harnessed the power of biomarkers, particularly circulating tumor DNA, to guide treatment selection, ultimately aiming to enhance patient outcomes and overall quality of life.
Progress of ctDNA in predicting prognosis of patients with urological tumors

Progress of ctDNA in predicting prognosis of patients with urological tumors

2023.10.13
Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was held from April 14 to 19, 2023, in Orlando, USA. In this AACR conference, three ctDNA-related studies evaluated its application value in urological tumors.